Investment Rating - The report assigns an "Outperform" rating to multiple companies in the discretionary consumption sector, including Nike, Li Ning, Midea Group, JD Group, Haier Smart Home, Gree Electric, Anta Sports, and many others [1]. Core Insights - The discretionary consumption sector has experienced a significant pullback due to the hawkish stance of the Federal Reserve, leading to a decline in global asset prices [4][13]. - The report highlights that the domestic sportswear sector has shown resilience, with a weekly increase of 0.6%, while other sectors such as luxury goods and cosmetics have faced declines [5][15]. - The report notes that various sub-sectors within discretionary consumption have performed differently, with gold and jewelry being the top performers in the recent weeks [4][13]. Summary by Relevant Sections Weekly Performance Review - The report details the weekly performance of various sectors, indicating that domestic sportswear outperformed others with a 0.6% increase, while luxury goods saw a decline of 5.8% [4][13]. - Monthly performance shows gold and jewelry leading with a 14.8% increase, while luxury goods and overseas sportswear faced significant declines [4][13]. Sector Analysis - The domestic sportswear sector's growth is attributed to increased demand for warm clothing due to colder weather and strategic partnerships, such as Anta Sports' acquisition of a stake in PUMA [6][15]. - The credit card sector experienced mixed results, with Mastercard performing well while Visa and American Express faced declines due to varying financial performance [15]. - The retail sector saw a decline of 1.4%, with some companies like China Resources Vanguard performing well due to favorable policies [15]. Valuation Analysis - The report indicates that the expected PE ratios for various sectors in 2025 are below their historical averages, suggesting potential investment opportunities [11][18]. - For instance, the expected PE for the domestic sportswear sector is 13.4 times, which is 70% of its past five-year average [11][18].

Investment Rating - The report maintains an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, while China National Pharmaceutical Group is rated "Neutral" [1]. Core Insights - The Hong Kong healthcare sector experienced a broad-based correction due to capital pressures, with pharmaceutical distribution remaining relatively stable [4][28]. - The Hang Seng Healthcare Index fell by 3.0% this week, underperforming the Hang Seng Index by 5.4 percentage points, but has gained 8.6% year-to-date, outperforming the Hang Seng Index by 1.7 percentage points [14][27]. - The top five gainers in the sector included Leads Biolabs-B (+19.3%), Sihuan Pharmaceutical (+17.9%), and Tigermed (+7.6%), while the bottom five decliners included Medlive Technology (-16.2%) and Laekna-B (-14.1%) [4][29]. Summary by Sections Market Performance - The report indicates that various sub-sectors within the healthcare market have experienced declines, with pharmaceutical distribution down by 0.3%, internet healthcare down by 2.1%, and medical devices down by 5.0% [4][28]. Company Updates - Rongchang Biopharmaceutical announced a revenue forecast of 3.25 billion yuan for 2025, representing a year-on-year increase of 89%, and has turned a profit [11]. - A collaboration agreement was signed between CSPC Pharmaceutical and AstraZeneca, involving a total payment of $18.5 billion for the licensing of GLP-1 long-acting assets [11]. - AstraZeneca plans to invest $15 billion in China by 2030, focusing on expanding drug manufacturing and R&D capabilities [12]. - Kangzheng Pharmaceutical's lebrikizumab cream has been approved for the treatment of non-segmental vitiligo in patients aged 12 and older [12]. Regulatory Developments - The National Health Commission approved a pilot program for internet-based first consultations in Beijing, which is expected to accelerate prescription outflow [13].

Investment Rating - The report does not explicitly state an investment rating for CSPC Pharmaceutical Group Core Insights - CSPC Pharmaceutical Group has entered into a strategic collaboration and licensing agreement with AstraZeneca, focusing on innovative peptide molecule discovery and long-acting delivery products [1][7] - AstraZeneca will receive exclusive global rights (excluding certain regions) to develop, manufacture, and commercialize innovative long-acting peptide drugs based on CSPC's technology platforms [2][8] - This collaboration marks the third partnership between CSPC and AstraZeneca, highlighting CSPC's competitive edge in innovative drug development [4][11] Financial Terms - AstraZeneca will pay a total upfront payment of USD 1.2 billion, with CSPC Jushi Biomedicine receiving 35% of this amount [3][9] - AstraZeneca is also committed to milestone payments of up to USD 3.5 billion for development and up to USD 13.8 billion for sales, with CSPC Jushi Biomedicine entitled to receive payments based on pipeline progress [3][10] - Additionally, AstraZeneca will pay tiered royalties up to the low-double digits on net sales of all licensed products [3][10] Collaboration Framework - The collaboration includes one clinical-ready asset, SYH2082, which is a long-acting GLP-1R/GIPR dual agonist advancing to Phase I clinical trials, and three preclinical-stage research projects [8] - The partnership will also explore four additional new projects based on the established technology platforms [2][8] Pipeline and Future Outlook - CSPC's pipeline includes high-quality assets such as an EGFR ADC, a PDE4B inhibitor, and ACTIIA/ACTIIB monoclonal antibodies, with over 20 innovative drug assets entering clinical stages annually [4][12] - The report expresses optimism regarding the sustained global competitiveness and future out-licensing opportunities for CSPC's other assets [12]

Investment Rating - The report maintains an "Outperform" rating for Sands China [2][16]. Core Insights - The company achieved net revenue of USD 2.058 billion in Q4 2025, representing a year-over-year increase of 16.2%. Adjusted property EBITDA reached USD 608 million, up 6.5% year-over-year, with an adjusted property EBITDA margin of 29.5% [4][12][15]. - The performance of the company's properties varied, with The Venetian and Plaza showing net revenue increases both year-over-year and quarter-over-quarter, while The Parisian and Sands underperformed [13][14]. - The company's gaming gross revenue increased significantly to USD 2.02 billion, up 23.1% year-over-year, driven by growth in VIP and premium mass segments [5][14]. - The adjusted EBITDA margin declined to 29.5%, down 2.7 percentage points year-over-year, primarily due to a shift in business structure and rising operating costs [6][15]. - The company's market share improved to 24.4% in Q3 2025, up from 23.7% in Q3 2024, indicating a positive trend in competitive positioning [7]. Financial Projections - The company is expected to generate net revenues of USD 7.937 billion and USD 8.363 billion for FY 2026 and FY 2027, respectively, with growth rates of 6.2% and 5.4% [16]. - Gaming gross revenue is projected to be USD 7.652 billion and USD 8.082 billion for FY 2026 and FY 2027, reflecting year-over-year growth of 6.6% and 5.6% [16]. - Adjusted property EBITDA is forecasted to reach USD 2.483 billion and USD 2.643 billion for FY 2026 and FY 2027, with corresponding margins of 31.3% and 31.6% [16].

Investment Rating - The report maintains an "Outperform" rating for Zai Lab with a target price of HKD 35.25, while the current price is HKD 13.82 [2][10]. Core Insights - Zai Lab is expected to achieve product net revenue of USD 465 million in FY25, representing a year-on-year growth of 16.5%. The core product efgartigimod is projected to generate USD 97.96 million, with a gross profit margin of 61.0% [3][16]. - The management has reaffirmed a dual-engine strategy focusing on introducing high-quality overseas products for commercialization in China and leveraging a cross-border R&D platform for efficient global market development [4][17]. - Despite a downward revision in revenue guidance for 2025 and a delay in profitability targets, the company has a robust portfolio with eight products approved in China and several differentiated global assets in its pipeline [4][17]. Financial Performance - Revenue forecasts for FY25, FY26, and FY27 have been adjusted to USD 465 million, USD 501 million, and USD 717 million, respectively. Net loss forecasts for the same periods are revised to USD 180 million, USD 159 million, and USD 55 million [10][19]. - R&D expenses are expected to be USD 205 million, a decrease of 12.8% year-on-year, while SG&A expenses are projected at USD 284 million, down 5.0% [3][16]. Clinical Development Pipeline - Zocilurtatug (DLL3 ADC) is set to initiate three registrational clinical trials by the end of 2026, targeting small cell lung cancer and neuroendocrine carcinoma [5][21]. - Several early-stage products, including ZL-1503, ZL-6201, ZL-1222, and ZL-1311, are expected to contribute to long-term global value creation [6][9][21].

Investment Rating - The report maintains an "Outperform" rating for Cirrus Aircraft [2][9]. Core Insights - Cirrus Aircraft's strong competitive advantage is attributed to its extensive network of service and training sites, combined with user-friendly products. The company has approximately 260 service locations globally, including 193 authorized service centers in major U.S. regions [3][10]. - The company is projected to deliver around 800 aircraft in 2025, with an optimistic outlook for new orders, expecting approximately 600 new orders for the year. The SR2X series is expected to see a 10% year-on-year increase in deliveries [4][11]. - The average selling price for the SR2X series is anticipated to rise to approximately US$1.19 million, while the Vision Jet's average price is expected to increase to US$3.45 million, contributing to improved profit margins [4][11]. Financial Projections - Revenue projections for Cirrus Aircraft are set at US$1.394 billion for 2025, US$1.674 billion for 2026, and US$1.951 billion for 2027, with corresponding net profits of US$159 million, US$183 million, and US$204 million [5][13]. - The overall gross profit margin is expected to increase by 0.9 percentage points year-on-year, while the net profit margin is projected to rise by 1.1 percentage points [4][11]. Valuation - The target price for Cirrus Aircraft has been raised to HK$70.20, based on a PE ratio of 18x applied to the expected EPS for 2026 [5][13].

Investment Rating - The report maintains an "OUTPERFORM" rating for ANTA Sports, with a target price of HK$91.40, representing a potential upside of 17.4% from the current price of HK$77.90 [2][14]. Core Insights - ANTA Group plans to acquire a 29.06% stake in PUMA SE for €1.5 billion (approximately RMB 12.278 billion), becoming its largest shareholder. The acquisition price of €35 per share represents a 60% premium over the market price, but management believes it is justified based on enterprise value assessments [3][11]. - The acquisition is part of ANTA's strategy to enhance its "Single Focus, Multi-Brand, Globalization" approach, aiming to fill gaps in its global presence and validate its multi-brand management model [4][12]. - The transaction is expected to be completed by the end of 2026, subject to various regulatory approvals, including antitrust and foreign direct investment approvals [3][11]. Financial Summary - Revenue forecasts for ANTA Sports from 2025 to 2027 are projected at RMB 78.26 billion, RMB 85.00 billion, and RMB 92.04 billion, reflecting year-on-year growth rates of 10.5%, 8.6%, and 8.3% respectively [7][14]. - Net profit attributable to the parent company is expected to be RMB 12.98 billion in 2025, with a decline in 2026 to RMB 14.34 billion, and an increase to RMB 16.24 billion in 2027, showing a year-on-year change of -16.6%, 10.0%, and 12.6% [7][14]. - The projected P/E ratios for 2025, 2026, and 2027 are 15.0x, 13.6x, and 12.1x respectively [7][14]. Market Context - PUMA's revenue is expected to decline in 2025, with a consensus forecast of a net loss of €620 million. The brand's sales are primarily through franchising, which accounts for 72.5% of its revenue [5][13]. - PUMA has strong brand recognition in segments such as running, football, and motorsports, particularly in markets where ANTA has a weaker presence, such as Europe and Latin America [5][13].

Investment Rating - The report assigns an "Outperform" rating to multiple companies including Nike, Midea Group, JD Group, Haier Smart Home, Gree Electric, Anta Sports, and many others, indicating a positive outlook for these stocks [1]. Core Insights - The gold and jewelry sector has emerged as the top performer this week, driven by new consumer sentiment and the upcoming Spring Festival, which is expected to boost sales [4][14]. - The overall performance of various sectors shows significant fluctuations, with gold and jewelry leading the gains, while sectors like luxury goods and U.S. hotels are experiencing declines [12][15]. - The report highlights that the valuation of various sectors remains below their historical averages, suggesting potential investment opportunities [10][17]. Sector Performance Summary - **Gold and Jewelry**: This sector saw a weekly increase of 12.9%, with notable stock performances from Lao Pu Gold (+20.5%) and Chao Hong Ji (+12.3%) due to positive sales forecasts [6][14]. - **Gambling**: The gambling sector increased by 2.9%, with companies like MGM China and Galaxy Entertainment showing strong market share growth [14]. - **Overseas Cosmetics**: This sector rose by 2.1%, driven by E.L.F. Beauty's stock increase of 4.6% following positive earnings forecasts [14]. - **Retail**: The retail sector increased by 2.0%, with Wanchen Group's stock rising by 14.3% due to optimistic revenue expectations [14]. - **Domestic Cosmetics**: This sector saw a modest increase of 0.9%, with companies like Proya and Runben showing positive stock movements [8][14]. - **Snacks**: The snack sector increased by 0.6%, with Youyou Foods and Qiaqia Foods showing gains [14]. - **Pet Sector**: This sector experienced a slight decline of 0.4%, with Zhongchong Co. facing stock price pressures [14]. - **Domestic Sportswear**: This sector decreased by 1.4%, with Anta Sports experiencing a notable decline of 6.1% [14]. - **U.S. Hotels**: This sector fell by 1.4%, with major hotel chains like Marriott and Hilton reporting declines [15]. - **Credit Cards**: The credit card sector also saw a decline of 1.4%, influenced by uncertainties regarding proposed interest rate caps [15]. - **Luxury Goods**: This sector decreased by 1.6%, with Burberry facing significant stock price drops due to market concerns [15]. - **Overseas Sportswear**: This sector fell by 1.8%, with Adidas experiencing a notable drop of 8.7% due to downgrades from investment banks [16]. Valuation Analysis - The report indicates that the expected PE ratios for various sectors in 2025 are below their historical averages, suggesting potential undervaluation. For example, the expected PE for the gold and jewelry sector is 25.9, which is 49% of its historical average [10][17].

Investment Rating - The report maintains an "Outperform" rating for Laopu Gold [2][12] Core Insights - Laopu Gold's revenue is expected to grow by 217% year-on-year in 2025, reaching RMB 26.96 billion, with a projected net profit of RMB 4.63 billion, reflecting a 214% increase [3][12] - The company is focusing on deepening its domestic and overseas offline expansion, with a strategy of "fewer but better, larger and more beautiful" in site selection, enhancing per-store sales efficiency [4][10] - Differentiated original designs are driving product iterations, with new product contributions expected to rise, including exclusive launches targeting diverse consumer groups [5][11] Revenue and Profit Forecast - Revenue projections for 2025, 2026, and 2027 are RMB 26.96 billion, RMB 36.03 billion, and RMB 43.78 billion, respectively, with year-on-year growth rates of 217%, 33.6%, and 21.5% [6][12] - Attributable net profit forecasts for the same years are RMB 4.63 billion, RMB 6.51 billion, and RMB 8.19 billion, with growth rates of 214.3%, 40.6%, and 25.8% [6][12] Market Position and Strategy - Laopu Gold plans to open approximately 5 new stores in high-end districts and upgrade existing ones, focusing on high-density and strong presence in core cities [4][10] - The company has expanded its international presence with the opening of its first overseas store in Singapore, enhancing brand internationalization [4][10] Product Development - The company has a clear cadence for new product launches, with several unique designs introduced throughout 2025, aimed at appealing to contemporary consumer aesthetics [5][11]

Investment Rating - The report maintains an "OUTPERFORM" rating for Baidu Group [2] Core Views - Baidu's operating cash flow is expected to remain positive in Q4, supported by prudent spending and the integration of AI tools in operations [4][13] - The listing of Kunlun Chip (KLX) is anticipated to unlock significant valuation for Baidu, with potential revenue comparable to Cambricon [5][14] - Apollo Go is set to accelerate its global expansion in 2026, which may further support Baidu's stock performance [15] Financial Summary - Baidu's revenue for FY25 is projected at RMB 128.7 billion, a decrease of 2.4% year-on-year, with a net profit of RMB 18.6 billion, down 31% [3][11] - The core business is expected to generate an adjusted operating profit of RMB 14.1 billion, corresponding to a margin of 13.8% [11] - For Q4, total core revenue is estimated at RMB 25.8 billion, reflecting a year-on-year decline of 6.9% but a quarter-on-quarter increase of 4.5% [12] Valuation and Recommendations - The report employs a Sum-of-the-Parts (SoTP) valuation method, estimating a total market cap of approximately HK$481.8 billion or a target price of HK$178, corresponding to a 24x PE for FY26 [6][14] - The valuation breakdown includes traditional search ads, AI cloud, AI SaaS, AI ads, and other segments, with significant contributions from the Robotaxi and Kunlun Chip businesses [6][15]